To date, we have only generated revenue through customer testing fees, but have not generated any revenue from technology licensing or service fees or product sales, and we do not anticipate generating any revenue from the sale of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. During the period from December 2018 (inception) through June 30, 2023, we have incurred cumulative net losses of approximately $25 million. Our future expenditures and capital requirements will depend on numerous factors, including, among others, the progress of our research and development efforts, deployment of pilot plants with key customers, and our ability to scale up to commercial operations.
As of June 30, 2023, we have raised capital by exempt offerings of common stock, preferred stock and convertible notes of approximately $39 million, net of offering costs and commissions.
From February 2021 to September 2021, the Company offered its securities through a registered funding portal Netcapital in a side-by-side offering of Common Stock, under registration exemptions Section 4(a)(6) and Regulation D, Rule 506(c), raising an aggregate $4,465,844.
On April 1, 2021, the Company completed a Regulation D, Rule 506(b) exempt equity financing issuing 3,407,142 shares of Preferred Series A stock for total proceeds of $5,565,000 before fees and commissions.
During the second half of 2021, the Company received funding of approximately $2.8 million from the issuance of convertible notes.
During the first quarter of 2022, the Company raised approximately $250,000 through the issuance of convertible notes. In September 2022 the Company raised an additional $2 million through the issuance of convertible promissory notes to its founder and a board member, making the total raised through convertible promissory notes to this date approximately $4.8 million.
On September 30, 2022, the Company held its first closing under its Regulation A+ offering, which was filed with the SEC through a Form 1-A Offering Circular and qualified on July 6, 2022, and received approximately $6.9 million through the sale of Common Stock, net of offering costs and commissions.
During December 2022, the Company raised $15 million through the sale of Series B Preferred Stock in connection with the Series B Preferred Stock Offering. In connection with the closing of such Series B Offering, all of the Company’s existing promissory convertible notes, both principal and interest of 7% per annum, were converted into 1,496,610 shares of Series B Preferred Stock, calculated as of December 15, 2022, including a 15% discount to the per-share-price of the Series B Preferred Stock.
The Company did not raise any capital during the first quarter of 2023. As of June 30, 2023, two investors signed Joinder Agreements to the Series B Offering and the Company subsequently raised an additional approximately $16.5 million through the sale of Series B Preferred Stock.
An immaterial amount of employee or contractor stock options were exercised during the second quarter of 2023 as recorded on the Statement of Changes in Stockholders’ Equity.
These funds have provided us the ability to build pilot and demonstration plants that we plan to deploy to facilities or test beds at or near our customers, as well as advance our work and plans on the demonstration and commercial facilities. We continuously monitor our use of funds relative to executing on our business strategy with a focus on spending capital that will further our ability to recognize revenue in the future. We balance our use of funds based on our ability to raise additional capital resources through various exempt offerings as well as this Offering Statement.
We believe that we currently have sufficient capital to finance our operations at least through the end of Q2 2024. However, in order to continue the growth of our business and expansion of the Company, we may need to obtain additional financing. Further, we expect that, after such period, we will be required to raise additional capital to fund our operations and to further advance the commercialization of LiTAS™ in South America and the US. There is no assurance that such financing will be available when needed, or that ultimately, we will achieve profitable operations and positive cash flow.
Credit Facilities
During 2021 and 2022, the Company issued various convertible promissory notes to support its business operations, aggregating to a total of $4.8 million by the end of 2022. In December 2022, all convertible promissory notes outstanding were converted as part of our Series B Preferred Stock Offering. Management may decide to continue to issue convertible debt instruments to fund its operations if such capital is available in the market at reasonable rates. The Company has not entered into any credit facility with a bank or financial institution at this time.
Capital Expenditures
The Company spent $1,455,540 of cash on purchase of fixed assets during the six months ended June 30, 2023 and $626,417 of ca sh on purchase of fixed assets during the six months ended June 30, 2022. This increase is a result of higher spending on capital equipment as we scale our
laboratory equipment, office and IT equipment, and equipment for anticipated pilot and demonstration plant deployments. The Company expects that it will continue acquiring capital equipment to expand its operations and development plans.
4